Abivax Gains FDA Alignment on NDA Path for Obefazimod—Paving Way for 2026 Filing in Ulcerative Colitis
Market Chameleon (Fri, 31-Jul 7:08 AM)
Abivax Secures $920 Million Through Full Exercise of Underwriters' Option: Funding Fuels Late-Stage IBD Drug Push
Market Chameleon (Thu, 2-Jul 11:44 AM)
Abivax’s $800M Upsized ADS Offering Priced at Premium: Extended Cash Runway Signals Ambitious US Plans
Market Chameleon (Wed, 1-Jul 8:58 AM)
Abivax Reports Meaningful Long-Term Efficacy and Safety Results for Obefazimod in Refractory Ulcerative Colitis
Market Chameleon (Tue, 30-Jun 10:29 AM)
